<DOC>
	<DOC>NCT01071226</DOC>
	<brief_summary>T cell depletion utilizing the CliniMACS device will allow more precise, specific and controlled graft engineering of peripheral blood stem cells from unrelated and partially matched related donors without an increase in relapse or graft rejection and grade III or IV acute graft versus host disease (GVHD).</brief_summary>
	<brief_title>Peripheral Blood Stem Cell Transplantation Using the CliniMACS Device</brief_title>
	<detailed_description />
	<mesh_term>Pancytopenia</mesh_term>
	<mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
	<criteria>All races are eligible Malignant diseases: Leukemias and Lymphomas Nonmalignant diseases: Severe Aplastic Anemia, immunodeficiencies Lansky or Karnofsky &gt; 70 Echo &gt; 27% shortening fraction renal function:serum creatinine &lt; 1.5 x for normal age no active untreated infection DLCO &gt; 50% of predicted value Hepatic: AST and ALT &lt; 3x upper limit of normal; bilirubin &lt; 2.0.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>22 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Malignant and non-malignant diseases</keyword>
	<keyword>Hematopoietic stem cell transplant</keyword>
	<keyword>Peripheral blood progenitor cell transplant</keyword>
	<keyword>CliniMACS device</keyword>
	<keyword>T cell depletion</keyword>
</DOC>